Novel insight into mutational landscape of head and neck squamous cell carcinoma

Development of head and neck squamous cell carcinoma (HNSCC) is characterized by accumulation of mutations in several oncogenes and tumor suppressor genes. We have formerly described the mutation pattern of HNSCC and described NOTCH signaling pathway alterations. Given the complexity of the HNSCC, h...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 3; p. e93102
Main Authors Gaykalova, Daria A, Mambo, Elizabeth, Choudhary, Ashish, Houghton, Jeffery, Buddavarapu, Kalyan, Sanford, Tiffany, Darden, Will, Adai, Alex, Hadd, Andrew, Latham, Gary, Danilova, Ludmila V, Bishop, Justin, Li, Ryan J, Westra, William H, Hennessey, Patrick, Koch, Wayne M, Ochs, Michael F, Califano, Joseph A, Sun, Wenyue
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 25.03.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Development of head and neck squamous cell carcinoma (HNSCC) is characterized by accumulation of mutations in several oncogenes and tumor suppressor genes. We have formerly described the mutation pattern of HNSCC and described NOTCH signaling pathway alterations. Given the complexity of the HNSCC, here we extend the previous study to understand the overall HNSCC mutation context and to discover additional genetic alterations. We performed high depth targeted exon sequencing of 51 highly actionable cancer-related genes with a high frequency of mutation across many cancer types, including head and neck. DNA from primary tumor tissues and matched normal tissues was analyzed for 37 HNSCC patients. We identified 26 non-synonymous or stop-gained mutations targeting 11 of 51 selected genes. These genes were mutated in 17 out of 37 (46%) studied HNSCC patients. Smokers harbored 3.2-fold more mutations than non-smokers. Importantly, TP53 was mutated in 30%, NOTCH1 in 8% and FGFR3 in 5% of HNSCC. HPV negative patients harbored 4-fold more TP53 mutations than HPV positive patients. These data confirm prior reports of the HNSCC mutational profile. Additionally, we detected mutations in two new genes, CEBPA and FES, which have not been previously reported in HNSCC. These data extend the spectrum of HNSCC mutations and define novel mutation targets in HNSCC carcinogenesis, especially for smokers and HNSCC without HPV infection.
Bibliography:Competing Interests: The authors have read the journal's policy and have the following conflicts: 1. Co-author Joseph A. Califano is a PLOS ONE Editorial Board member. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. 2. Co-authors Elizabeth Mambo, Ashish Choudhary, Jeffery Houghton, Kalyan Buddavarapu, Tiffany Sanford, Will Darden, Alex Adai, Andrew Hadd, and Gary Latham are employed by Asuragen Inc., Austin, Texas. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Current address: Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, United States of America
Conceived and designed the experiments: DAG WS JAC EM GL. Performed the experiments: JH KB TS AH. Analyzed the data: DAG WS EM AC GL WD AA LVD MFO. Contributed reagents/materials/analysis tools: EM AH JB RL WHW PH WMK JAC. Wrote the paper: DAG WS JAC. Revised the manuscript: GL EM AC LVD. Supervised the NGS data processing: AA.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0093102